Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Department of Molecular Oncology (2006-2014 Dept of Cancer Prev.)
25 publications found
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks
EBioMedicine, 18, 83-93
DOI 10.1016/j.ebiom.2017.04.006, PubMed 28412251
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Ann Oncol, 28 (5), 1023-1031
DOI 10.1093/annonc/mdx052, PubMed 28453697
A protein kinase A-ezrin complex regulates connexin 43 gap junction communication in liver epithelial cells
Cell Signal, 32, 1-11
DOI 10.1016/j.cellsig.2017.01.008, PubMed 28077322
CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
Sci Rep, 7 (1), 16618
DOI 10.1038/s41598-017-16747-x, PubMed 29192179
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
Sci Rep, 7 (1), 17978
DOI 10.1038/s41598-017-18210-3, PubMed 29269934
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
Mol Oncol, 11 (9), 1156-1171
DOI 10.1002/1878-0261.12086, PubMed 28556483
chimeraviz: a tool for visualizing chimeric RNA
Bioinformatics, 33 (18), 2954-2956
DOI 10.1093/bioinformatics/btx329, PubMed 28525538
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630
The connexin 43 C-terminus: A tail of many tales
Biochim Biophys Acta Biomembr, 1860 (1), 48-64
DOI 10.1016/j.bbamem.2017.05.008, PubMed 28526583
Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients
Clin Epigenetics, 9, 97
DOI 10.1186/s13148-017-0397-4, PubMed 28878843
An update on minding the gap in cancer
Biochim Biophys Acta Biomembr, 1860 (1), 237-243
DOI 10.1016/j.bbamem.2017.06.015, PubMed 28655619
Involvement of DPP9 in gene fusions in serous ovarian carcinoma
BMC Cancer, 17 (1), 642
DOI 10.1186/s12885-017-3625-6, PubMed 28893231
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Genome Med, 9 (1), 46
DOI 10.1186/s13073-017-0434-0, PubMed 28539123
The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions
J Cell Sci, 130 (17), 2867-2882
DOI 10.1242/jcs.202408, PubMed 28733455
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Cell Rep, 19 (10), 2045-2059
DOI 10.1016/j.celrep.2017.05.049, PubMed 28591577
Bromodomain-containing proteins in prostate cancer
Mol Cell Endocrinol, 462 (Pt A), 31-40
DOI 10.1016/j.mce.2017.06.007, PubMed 28624514
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
Semin Cancer Biol, 51, 36-49
DOI 10.1016/j.semcancer.2017.12.004, PubMed 29253542
CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
Int J Cancer, 141 (5), 967-976
DOI 10.1002/ijc.30796, PubMed 28542846
Novel transcription-induced fusion RNAs in prostate cancer
Oncotarget, 8 (30), 49133-49143
DOI 10.18632/oncotarget.17099, PubMed 28467780
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer
BMC Genomics, 18 (1), 270
DOI 10.1186/s12864-017-3620-y, PubMed 28359301